{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:41:21Z","timestamp":1769636481924,"version":"3.49.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) remains the cornerstone of treatment for muscle-invasive bladder cancer (MIBC). While platinum-based regimens have demonstrated benefits in tumor downstaging and improved long-term survival for selected patients, they may pose risks for those who are ineligible or unresponsive to chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>We undertook a bibliometric analysis to elucidate the breadth of literature on NAC in bladder cancer, discern research trajectories, and underscore emerging avenues of investigation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic search of the Web of Science Core Collection (WoSCC) was conducted to identify articles pertaining to NAC in bladder cancer from 1999 to 2022. Advanced bibliometric tools, such as VOSviewer, CiteSpace, and SCImago Graphica, facilitated the examination and depicted the publication trends, geographic contributions, institutional affiliations, journal prominence, author collaborations, and salient keywords, emphasizing the top 25 citation bursts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our analysis included 1836 publications spanning 1999 to 2022, indicating a growing trend in both annual publications and citations related to NAC in bladder cancer. The United States emerged as the predominant contributor in terms of publications, citations, and international collaborations. The University of Texas was the leading institution in publication output. \u201cUrologic Oncology Seminars and Original Investigations\u201d was the primary publishing journal, while \u201cEuropean Urology\u201d boasted the highest impact factor. Shariat, Shahrokh F., and Grossman, H.B., were identified as the most prolific and co-cited authors, respectively. Keyword analysis revealed both frequency of occurrence and citation bursts, highlighting areas of concentrated study. Notably, the integration of immunochemotherapy is projected to experience substantial growth in forthcoming research.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our bibliometric assessment provides a panoramic view of the research milieu surrounding neoadjuvant chemotherapy for bladder cancer, encapsulating the present state, evolving trends, and potential future directions, with a particular emphasis on the promise of immunochemotherapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1297542","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T04:22:31Z","timestamp":1708316551000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues"],"prefix":"10.3389","volume":"15","author":[{"given":"Yi","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengxiao","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zefeng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yitong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weibin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghua","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JunJiong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianqiu","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","article-title":"Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice","volume":"20","author":"van Hoogstraten","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.05.101","article-title":"Radical cystectomy for bladder cancer today\u2013a homogeneous series without neoadjuvant therapy","volume":"21","author":"Madersbacher","year":"2003","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.juro.2006.03.038","article-title":"Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era","volume":"176","author":"Hautmann","year":"2006","journal-title":"J Urol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1464-410x.1988.tb09152.x","article-title":"Pre-emptive (neo-adjuvant) intravenous chemotherapy for invasive bladder cancer","volume":"61","author":"Raghavan","year":"1988","journal-title":"Br J Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103795","article-title":"Neoadjuvant therapy for muscle-invasive bladder cancer: Current clinical scenario, future perspectives, and unsolved questions","volume":"178","author":"Ruiz de Porras","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10524.x","article-title":"Early comparison of nephrectomy options in children (open, transperitoneal laparoscopic, laparo-endoscopic single site (LESS), and robotic surgery)","volume":"109","author":"Kim","year":"2012","journal-title":"BJU Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.annonc.2022.01.075","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Moschini","year":"2022","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3390\/biology12070997","article-title":"Next-generation sequencing technology: current trends and advancements","volume":"12","author":"Satam","year":"2023","journal-title":"Biol (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in bladder cancer biology and therapy","volume":"21","author":"Tran","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0703-1","article-title":"Molecular profiling for precision cancer therapies","volume":"12","author":"Malone","year":"2020","journal-title":"Genome Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01003","article-title":"Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer","volume":"39","author":"Rose","year":"2021","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.05.011","article-title":"Checkpoint inhibitors in urothelial carcinoma-future directions and biomarker selection","author":"Meeks","year":"2023","journal-title":"Eur Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.999203","article-title":"The global research of bladder cancer immunotherapy from 2012 to 2021: A bibliometric analysis [Original Research]","volume":"12","author":"Qiu","year":"2022","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223994","article-title":"Visualizing a field of research: A methodology of systematic scientometric reviews","volume":"14","author":"Chen","year":"2019","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"B17","article-title":"CiteSpace II: visualization and knowledge discovery in bibliographic databases","author":"Synnestvedt","year":"2005","journal-title":"AMIA Annu Symp Proc"},{"key":"B18","volume-title":"Guidelines for interpreting the results of bibliometric analysis: A sensemaking approach","author":"Lim","year":"2024"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/21670811.2021.1957965","article-title":"Exploring data visualisations: an analytical framework based on dimensional components of data artefacts in journalism","volume":"11","author":"Stalph","year":"2023","journal-title":"Digital Journalism"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0507655102","article-title":"An index to quantify an individual\u2019s scientific research output","volume":"102","author":"Hirsch","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.65.9797","article-title":"Guideline on muscle-invasive and metastatic bladder cancer (European association of urology guideline): american society of clinical oncology clinical practice guideline endorsement","volume":"34","author":"Milowsky","year":"2016","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)02292-8","article-title":"Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.eururo.2003.09.019","article-title":"Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies","volume":"45","author":"Sherif","year":"2004","journal-title":"Eur Urol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(03)13580-5","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis","volume":"361","year":"2003","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.eururo.2005.04.005","article-title":"Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02051","article-title":"Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-020-1768-y","article-title":"Current status and future perspectives of immunotherapy in bladder cancer treatment","volume":"64","author":"Wu","year":"2021","journal-title":"Sci China Life Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discovery"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.01.014","article-title":"ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy","volume":"69","author":"Groenendijk","year":"2016","journal-title":"Eur Urol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq333","article-title":"BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer","volume":"22","author":"Font","year":"2011","journal-title":"Ann Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.02.003","article-title":"Defects in DNA repair genes confer improved long-term survival after cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"3","author":"Miron","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.07.023","article-title":"Assessment of predictive genomic biomarkers for response to cisplatin-based neoadjuvant chemotherapy in bladder cancer","volume":"83","author":"Gil-Jimenez","year":"2023","journal-title":"Eur Urol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003732","article-title":"Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study","volume":"18","author":"Chauhan","year":"2021","journal-title":"PloS Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3233\/blc-170110","article-title":"Quantitative assessment of heterogeneity in bladder tumor MRI diffusivity: can response be predicted prior to neoadjuvant chemotherapy","volume":"3","author":"Nguyen","year":"2017","journal-title":"Bladder Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8052212","article-title":"Recent advances and next breakthrough in immunotherapy for cancer treatment","volume":"2022","author":"Yang","year":"2022","journal-title":"J Immunol Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","article-title":"Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired","volume":"23","author":"Marei","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2017.01.002","article-title":"Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer","volume":"54","author":"Buttigliero","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109772","article-title":"Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma","volume":"256","author":"Zhou","year":"2023","journal-title":"Clin Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/cu9.0000000000000204","article-title":"Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review","volume":"17","author":"Bantounou","year":"2023","journal-title":"Curr Urol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"5431","DOI":"10.3390\/cancers14215431","article-title":"Targeted therapies in advanced and metastatic urothelial carcinoma","volume":"14","author":"Katims","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5900","article-title":"Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: A multi-center, single-arm, phase 2 study","volume":"12","author":"Han","year":"2023","journal-title":"Cancer Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2022.12.003","article-title":"A phase 1\/2 study of rapamycin and cisplatin\/gemcitabine for treatment of patients with muscle-invasive bladder cancer","volume":"21","author":"Makrakis","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34125","article-title":"Survival after neoadjuvant\/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer","volume":"151","author":"Einerhand","year":"2022","journal-title":"Int J Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.011","article-title":"Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study\u2606","volume":"31","author":"Bandini","year":"2020","journal-title":"Ann Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02694-9","article-title":"Nationwide study of real-world treatment patterns and clinical outcomes in patients with metastatic urothelial carcinoma in Hungary","volume":"40","author":"Maraz","year":"2023","journal-title":"Adv Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02763","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"41","author":"von der Maase","year":"2023","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","article-title":"The rediscovery of platinum-based cancer therapy","volume":"21","author":"Rottenberg","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1200\/jco.23.00363","article-title":"Perioperative chemoimmunotherapy with durvalumab for muscle-invasive urothelial carcinoma: primary analysis of the single-arm phase II trial SAKK 06\/17","volume":"41","author":"Cathomas","year":"2023","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.343","article-title":"Neoadjuvant nivolumab plus gemcitabine\/cisplatin chemotherapy in muscle-invasive urothelial carcinoma of the bladder","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res Treat"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04278-5","article-title":"Multi-omic machine learning predictor of breast cancer therapy response","volume":"601","author":"Sammut","year":"2022","journal-title":"Nature"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/s2589-7500(21)00215-6","article-title":"Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study","volume":"4","author":"Feng","year":"2022","journal-title":"Lancet Digit Health"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02134-1","article-title":"Multistain deep learning for prediction of prognosis and therapy response in colorectal cancer","volume":"29","author":"Foersch","year":"2023","journal-title":"Nat Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101348","article-title":"A CT-based deep learning radiomics nomogram for predicting the response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A multicenter cohort study","volume":"46","author":"Cui","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100382","article-title":"Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture","volume":"2","author":"Mi","year":"2021","journal-title":"Cell Rep Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.3390\/cancers13153903.","article-title":"Identification of CNGB1 as a predictor of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer","volume":"13","author":"Hepburn","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1297542\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T09:08:28Z","timestamp":1708420108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1297542\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2024.1297542"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1297542","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]},"article-number":"1297542"}}